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Lymphoblast modelThe recent discovery of heterozygous isocitrate dehydrogenase 2 (IDH2) mutations of residue Arg140 to
Gln140 or Gly140 (IDH2wt/R140Q, IDH2wt/R140G) in D-2-hydroxyglutaric aciduria (D-2-HGA) has deﬁned the
primary genetic lesion in 50% of D-2-HGA patients, denoted type II. Overexpression studies with
IDH1R132H and IDH2R172K mutations demonstrated that the enzymes acquired a new function, converting
2-ketoglutarate (2-KG) to D-2-hydroxyglutarate (D-2-HG), in lieu of the normal IDH reaction which revers-
ibly converts isocitrate to 2-KG. To conﬁrm the IDH2wt/R140Q gain-of-function in D-2-HGA type II, and to
evaluate potential therapeutic strategies, we developed a speciﬁc and sensitive IDH2wt/R140Q enzyme
assay in lymphoblasts. This assay determines gain-of-function activity which converts 2-KG to D-2-HG in
homogenates of D-2-HGA type II lymphoblasts, and uses stable-isotope-labeled 2-keto[3,3,4,4-2H4]gluta-
rate. The speciﬁcity and sensitivity of the assay are enhanced with chiral separation and detection of
stable-isotope-labeled D-2-HG by ultra performance liquid chromatography-tandem mass spectrometry
(UPLC-MS/MS). Eleven potential inhibitors of IDH2wt/R140Q enzyme activity were evaluated with this proce-
dure. The mean reaction rate in D-2-HGA type II lymphoblasts was 8-fold higher than that of controls and D-
2-HGA type I cells (14.4 nmol h−1 mg protein−1 vs. 1.9), with a corresponding 140-fold increase in intracel-
lular D-2-HG level. Optimal inhibition of IDH2wt/R140Q activity was obtained with oxaloacetate, which com-
petitively inhibited IDH2wt/R140Q activity. Lymphoblast IDH2wt/R140Q showed long-term cell culture stability
without loss of the heterozygous IDH2wt/R140Q mutation, underscoring the utility of the lymphoblast model
for future biochemical and therapeutic studies.eto[3,3,4,4-2H4]glutarate; 2H4-
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The discovery of recurrent mutations in isocitrate dehydrogenase 1
(IDH1) in patients with glioblastomamultiforme has rekindled interest
in NADP(H)-dependent isocitrate dehydrogenase enzymes [1]. A
high incidence of speciﬁc mutations in the active sites of cytosolic and
peroxisomal IDH1 (OMIM ID: 147700) (residue Arg132/R132) and themitochondrial homologue IDH2 (OMIM ID: 147650) (residues
Arg140/R140 and Arg172/R172) are found in a wide variety of hemato-
logic malignancies and solid tumors [2]. These mutations alter the en-
zymes normal capacity to convert isocitrate to 2-ketoglutarate (2-KG)
and confer on it a new function which converts 2-KG to D-2-hydroxy-
glutarate (D-2-HG), leading to accumulation of D-2-HG in solid tumor
cells and in plasma of patients with acute myeloid leukemia [3,4].
Supraphysiological D-2-HG concentrations in body ﬂuids are the
biochemical hallmark of the inborn errors of metabolism D-2-hydroxy-
glutaric aciduria (D-2-HGA) type I (OMIM ID: 600721) and type II
(OMIM ID: 613657). D-2-HGA type I is caused by various homozygous/
compound heterozygous mutations/deletions in the D2HGDH gene
encoding for D-2-hydroxyglutarate dehydrogenase (D-2-HGDH, OMIM
ID: 609186) [5], whereas D-2-HGA type II is caused primarily by the het-
erozygous de novo IDH2wt/R140Q mutation [6]. Thus far only one patient
was detected with an IDH2wt/R140G mutation. The phenotype of D-2-
HGA has a broad clinical spectrum ranging from asymptomatic to a se-
vere clinical presentation with heterogeneous MRI abnormalities ob-
served [7–10]. Another form of D-2-HGA is associated with
spondyloenchondromatosis, but the etiology is unknown [11]. The chiral
Fig. 1. Reactionmechanism catalyzed by IDH2wt/R140Q converting stable isotope labeled
2H4-2-KG into 2H4-D-2-HG with NADPH as electron donor.
1381M. Kranendijk et al. / Biochimica et Biophysica Acta 1812 (2011) 1380–1384counterpart of D-2-HG, L-2-hydroxyglutarate (L-2-HG), is increased in
patients with L-2-hydroxyglutaric aciduria (L-2-HGA, OMIM ID:
236792), a leukoencephalopathy associated with mutations in the
L2HGDH gene encoding for L-2-hydroxyglutarate dehydrogenase (L-2-
HGDH, OMIM ID: 609584) [12–14]. Whereas an increased incidence of
brain tumors is reported in L-2-HGA [15], currently no neoplastic malig-
nancies have been reported in D-2-HGA.
A speciﬁc enzyme assay using enantiomerically pure stable-isotope-
labeled D-2-HG was developed to assess the enzyme activity of D-2-
HGDH in cultured ﬁbroblasts and lymphoblasts, verifying that D-2-
HGDH was impaired in D-2-HGA type I patients [16]. An enzyme assay
to assess IDH2wt/R140Q-mutant enzyme activity in cultured human
cells from D-2-HGA type II patients has not been described. Several
groups used spectrophotometric assays to study IDH1R132H, IDH1R132C,
IDH2R140Q, IDH2R140W, and IDH2R172K enzyme activities via the NADP
(H) couple in overexpressed cells [3,4,17], yet this approach suffered
fromhigh background issues in extracts of cultured human cells. Pietrak
et al. improved the assay's characteristics by employing tandem mass
spectrometry to quantify 2-hydroxyglutarate, howeverwithout separa-
tion of D- and L-2-HG analytes [18].We sought to develop amore robust
assay system which could both verify the presence of the IDH2wt/R140Q
gain-of-function activity and simultaneously investigate potential ther-
apeutic inhibitors whichmight quantitatively decrease D-2-HG produc-
tion. Accordingly, we developed a new assay which determines
IDH2wt/R140Q activity in lymphoblast extracts using stable-isotope-
labeled 2-keto[3,3,4,4-2H4]glutarate (2H4-2-KG) as substrate. The reac-
tion product, D-2-[3,3,4,4-2H4]hydroxyglutarate (2H4-D-2-HG), is spe-
ciﬁcally detected by derivatization and chiral separation of D-2-HG
and L-2-HG using ultra performance liquid chromatography-tandem
mass spectrometry (UPLC-MS/MS). Further, this new assay facilitated
the preclinical evaluation of several endogenous metabolites for their
ability to inhibit IDH2wt/R140Q activity.
2. Materials and methods
2.1. Lymphoblast cell lines and protein extraction
All lymphoblast cell lines were obtained from Epstein–Barr virus
transfected lymphocytes and were anonymized. Five cell lines were
obtained from D-2-HGA type II patients which all carried the heterozy-
gous IDH2 c.[419 GNA], p.[Arg140Gln] (IDH2wt/R140Q)mutation and cell
culture stability was evaluated by conﬁrmation of the presence of the
heterozygous IDH2wt/R140Q mutation by DNA sequencing analysis. Ad-
ditionally, ﬁve cell lines obtained from healthy individuals served as
controls, supplemented with two cell lines obtained from D-2-HGA
type I patients which carried compound heterozygous mutations in
D2HGDH associated with impaired D-2-HGDH enzyme activity [5].
Lymphoblasts were grown in RPMI 1640 culture medium supple-
mented with 1% penicillin/streptomycin and 8% fetal bovine serum
(all from Invitrogen) until a sufﬁcient cell suspension was achieved to
obtain a cell pellet containing ~106 cells. Subsequently, cells were har-
vested by centrifugation (6 min 340 g), washed twice with Hank's bal-
anced salt solution and stored as a dry cell pellet at −80 °C prior to
analysis.
Cell pellets were suspended in 250 μL M-PER containing 1% HALT
protease/phosphatase inhibitor (Thermo Scientiﬁc), sonicated using
a Bandalin Sonopuls mini 20 titanium 1.5 mm probe for 10 s at 90%
power while cooled on ice, followed by centrifugation of the cell ex-
tract for 15 min at 14,000 g. The clariﬁed supernatant was transferred
to a 1.5 mL Eppendorf tube and gently mixed. Protein concentration
was determined with a Pierce BCA protein assay (Sigma-Aldrich).
2.2. Incubation and UPLC-MS/MS analysis
The assay was performed in duplicate for 30 min at 37 °C in 150 μL
buffer pH=7.5 containing 100 mM Tris–HCl, 5 mM MnCl2, 0.2 mMNADPH (Sigma-Aldrich), 15 mM 2-keto[3,3,4,4-2H4]glutarate (2H4-
2-KG) (Euriso-Top, Gif sur Yvette, France) with a ﬁnal protein con-
centration of 0.40 mg mL−1. The reaction was terminated by cooling
the samples on ice directly followed by protein removal via centrifu-
gation with Microcon Ultracel YM-10 kDa ﬁlters (Millipore) in a pre-
chilled centrifuge (15 min 20,000 g 4 °C). Twenty microliters of ﬁl-
trate was transferred to a 1.5 mL HPLC vial, mixed with 200 pmol
D/L-2-hydroxy[2-2H1]glutarate as internal standard in 200 μL metha-
nol, and dried with N2(g) at 40 °C (2H1-D/L-2-HG, made in-house
from unlabeled 2-KG by chemical reduction with zinc in deuterated
water [24]). Subsequently, 50 μL (+)-O,O′-Diacetyl-L-tartaric anhy-
dride (Datan, Aldrich) derivative reagent (50 mg mL−1 dissolved in
dichloromethane:acetic acid 80:20 (v/v)) was added, and the vials
were capped and heated 30 min 75 °C. Finally, the samples were
dried with N2(g) at 40 °C and dissolved in 500 μL mobile phase A (de-
tails below). Calibration lines of 10 to 400 pmol for each metabolite
were composed of unlabeled D/L-2-HG (Sigma) and 2H4-D/L-2-HG
(made in-house from 2H4-2-KG [24]). The substrate 2H4-2-KG is con-
verted by IDH2wt/R140Q into 2H4-D-2-HG (Fig. 1), and the latter is de-
termined by derivatization with Datan, followed by UPLC-MS/MS
analysis [19], as a measure of the enzyme activity. Since the method
allows the separation of D- and L-2-hydroxyglutarate, account was
taken of the fact that D-2-hydroxyglutarate amounts to half of the
total amount of 2-hydroxyglutarate in the standards.
For chromatographic analysis, aWaters Acquity UPLCwas equipped
with an HSS T3 column (2.1×100 mm 1.8 μm particle size) running at
0.4 mLmin−1 97% mobile phase A (120 mgmL−1 ammonium formate
pH=3.25) and 3% acetonitrile followed by a 40% acetonitrile wash
step. Injection volume was 5 μL and detection was performed with an
Applied Biosystems 4000 Q Trap mass spectrometer equipped with an
ESI Turbo Spray interface running in negative MRM mode: transitions
(m/z) D/L-2-HG=363.0N146.9; 2H1-D/L-2-HG=364.0N147.9; 2H4-
D/L-2-HG=367.0N150.9. Other settings included: CUR=10;
TEM=100; GS1=40; GS2=50; ihe=ON; IS=−4500; CAD=3;
DP=−20; EP=−5; CE=−12.5; CXP=−10. The retention times
were 2.8 min for L-2-HG and 3.4 min for D-2-HG (Fig. S1). Raw data pro-
cessing was performed using Analyst 1.4.2./MS Excel and concentra-
tions were extrapolated from calibration lines (Fig. S2).2.3. IDH2wt/R140Q inhibition
Eleven (endogenous) metabolites were selected based upon their
structural similarities with 2-KG, D-2-HG or isocitrate to test their ca-
pacity to reduce 2H4-D-2-HG production by IDH2wt/R140Q: D-2-HG,
L-2-HG, L-isocitrate (Ds-(+)-threo-isocitric acid monopotassium
salt), citrate, L-glutamate, L-glutamine, L-malate, D-malate, oxaloace-
tate, acetoacetate and acetoacetic acid methyl ester. Inhibitors were
evaluated at up to ~30 mM concentration. All other parameters
were held constant, as was the 2H4-2-KG substrate concentration of
15 mM. The pH of the reaction mixture was monitored before and
after incubation to verify constant experimental conditions, especially
important since IDH2wt/R140Q is sensitive to small pH changes. The Ki
of oxaloacetate was evaluated by determining the KM of 2H4-2-KG
with 0.0, 5.8 and 11.7 mM oxaloacetate supplemented in the reaction
mixture.
Fig. 3. Reaction rates (nmol h−1 mg protein−1) determined in cell homogenates of
controls (n=5, mean=1.8), D-2-HGA type I (n=2, mean=1.9) and D-2-HGA type II
cells (n=5, mean=14.4), error bars: 95% CI (SPSS 15.0).
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3.1. IDH2wt/R140Q gain-of-function enzyme assay
Optimal pH and concentrations of assay components (TRIS, MnCl2,
NADPH) were determined under conditions of the highest reaction
rates of IDH2wt/R140Q in cell lysates of D-2-HGA type II lymphoblasts
(data not shown). The reaction rate was stable over 60 min and the
reaction dependence on protein content was linear to 1.14 mg pro-
tein mL−1 (data not shown). Substrate dependence for IDH2wt/R140Q
was determined in D-2-HGA type II cells with KM, 2-KG=1.7 mM and
Vmax=13.9 nmol h−1 mg protein−1. The observed KM, 2-KG is of the
same magnitude as previously reported for IDH1R132H overexpressed
in cells: KM, 2-KG=0.965 mM [3] and KM, 2-KG=0.7 mM [18], whereas
no KM, 2-KG has been previously reported for IDH2-mutants. 2H4-D-2-
HG production was also detected in control cells as well, produced by
an unidentiﬁed enzyme, which had different characteristics of sub-
strate dependence as compared to IDH2wt/R140Q: KM, 2-KG=0.7 mM
and Vmax=2.0 nmol h−1 mg protein−1 (Fig. 2).
The mean reaction rate detected in control (n=5) and D-2-HGA
type I (n=2) lymphoblasts was 1.8 and 1.9 nmol h−1 mg protein−1
respectively, whereas in D-2-HGA type II (n=5) the mean reaction
rate was ~8 times higher: 14.4 nmol h−1 mg protein−1 (Fig. 3). This
resulted in increased intracellular D-2-HG concentrations in D-2-
HGA type II cells when compared to controls/D-2-HGA type I cells.
The mean endogenous D-2-HG (nmol mg protein−1) values were:
controls=0.11, D-2-HGA type I=1.80, and D-2-HGA type II=15.06
(Fig. 4). The higher concentration of D-2-HG in D-2-HGA type II com-
pared to type I is consistent with the trend observed in body ﬂuids as
previously reported [5,6]. Conversely, the intracellular L-2-HG con-
centrations were comparable among all twelve cell lines, verifying
the independence of this metabolite from D-2-HG (Fig. 5). Further-
more, small amounts of 2H4-L-2-HG were detected, which were also
equivalent between all cell lines. 2H4-L-2-HG most likely originates
from the nonspeciﬁc conversion of 2H4-2-KG via L-malate dehydroge-
nase, an NADH-dependent reaction [20]. In support of this observa-
tion, when NADPH was replaced by NADH in the assay buffer with
D-2-HGA type II cells, 2H4-L-2-HG production increased 24-fold,
whereas 2H4-D-2-HG production decreased 9-fold (data not shown).
The IDH2wt/R140Q assay demonstrated little diagnostic sensitivity
in ﬁbroblast homogenates in its ability to distinguish betweenFig. 2. Lineweaver-Burk plot showing the reciprocal reaction rate as a function of reciprocal
2H4-2-KG concentration for: (♦) IDH2wt/R140Q activity in D-2-HGA type II cell homogenate
[KM=1.7 mM and Vmax=13.9 nmol h−1 mg protein−1] and (○) unidentiﬁed enzyme in
control cell homogenate [KM=0.7 mM and Vmax=2.0 nmol h−1 mg protein−1].IDH2wt/R140Q enzyme activity and that observed in controls.
The 2H4-D-2-HG production in D-2-HGA type II lysates was only
twice that observed in controls/D-2-HGA type I cells, which
accounted for the observed intracellular D-2-HG accumulation as
well (data not shown).
3.2. IDH2wt/R140Q inhibition
From eleven metabolites used to screen for inhibition of
IDH2wt/R140Q, oxaloacetate was the most potent: the 2H4-D-2-HG pro-
duction was more than 50% reduced when equal concentrations
(15 mM) of substrate and inhibitor were used (Fig. 6). Decreasing re-
action rates and increasing KM for 2H4-D-2-HG were observed when
2-KG substrate dependence was tested for IDH2wt/R140Q with varying
oxaloacetate concentration and a Ki, oxaloacetate of 3.9 mM was com-
puted from the data (Fig. 6). Oxaloacetate functions as a competitive
inhibitor in IDH2wt/R140Q with a slightly lower selectivity compared to
2-KG, since Ki, oxaloacetate/KM, 2-KG=2.
4. Discussion
Biochemical mechanisms for heterozygous IDH1 and IDH2 muta-
tions have been recently summarized. IDH1 and IDH2 are NADP(H)-
dependent homodimers catalyzing the reversible conversion of iso-
citrate to 2-KG. Zhao et al. observed that heterodimer formation
between a wild type and mutant subunit (IDH1wt/R132H) resulted
in considerable loss of isocitrate to 2-KG catalytic activity, whileFig. 4. Endogenous intracellular D-2-HG concentrations (nmol mg protein−1) deter-
mined in cell homogenates of controls (n=5, mean=0.11), D-2-HGA type I (n=2,
mean=1.80) and D-2-HGA type II (n=5, mean=15.06), error bars: 95% CI (SPSS
15.0).
Fig. 5. Endogenous intracellular L-2-HG concentrations (nmol mg protein−1) determined in
cell homogenates of controls (n=5,mean=0.18), D-2-HGA type I (n=2,mean=0.19) and
D-2-HGA type II (n=5, mean=0.23), error bars: 95% CI (SPSS 15.0).
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this activity [21]. D-2-HG is formed from 2-KG and NADPH [3,4]
in cells that overexpress IDH1R132H and IDH2R172K. Pietrak et al.
demonstrated that IDH1wt/R132H subunits function independently,
resulting in a coupled reaction which produces 2-HG from isoci-
trate and NADP+ [18], as had been previously hypothesized by
Dang and Ward et al. Unfortunately, chiral differentiation of prod-
uct 2-HG was not performed to differentiate the level of D- and L-2-
HG production. In the coupled reaction sequence, isocitrate and
NADP+ are converted into 2-KG and NADPH via IDH1wt-subunit
catalysis, with subsequent production of 2-HG and NADP+ via
IDH1R132H-subunit catalysis. Further, Pietrak and co-workers dem-
onstrated production of 2-HG from 2-KG via IDH1 wild type
(IDH1wt/wt) catalysis, a reaction strongly inhibited by isocitrate.
This reaction might represent an additional source of D-2-HG in
humans in conjunction with the reaction catalyzed by
hydroxyacid-oxoacid transhydrogenase (HOT, OMIM ID: 611083)
[22]. HOT primarily converts gamma-hydroxybutyrate (GHB) to
succinic semialdehyde coupled to the reduction of 2-KG to D-2-
HG. However, HOT has speciﬁcity towards several other GHB-like
metabolites which serve as electron donors as well. These reactions
catalyzed by IDHwt/wt and HOT likely contribute to endogenous
D-2-HG production observed in the IDH2wt/R140Q enzyme assay
(Fig. 2), and most likely contributed a high proportion of the back-
ground activity in assays employing ﬁbroblast extracts.Fig. 6. [left] Inhibition of IDH2wt/R140Q reaction rate as a function of oxaloacetate concentration
substrate conc.=15mM); [right] Observed KM, 2-KG with different oxaloacetate concentrat
Ki, oxaloacetate=3.9 mM.The concentration of D-2-HG is increased 140 fold in lymphoblasts
from patients with IDH2wt/R140Q-mutations compared to controls,
whereas the enzymatic activity of D-2-HG production in cell free systems
is increased by only 8-fold. Perhaps, the larger difference observed for in-
tact cells is due to the fact that D-2-hydroxyglutarate dehydrogenase
(D-2-HGDH) consumes essentially all the D-2-HG that is formed in con-
trol cells, but due to limited capacity [23], it is incapable of metabolizing
all of the D-2-HG formed by IDH2wt/R140Q. Accordingly, the amount of
D-2-HG that accumulates in cells that are deﬁcient in D-2-HGDH (and
have a non-mutated IDH2) amounts to about 1/8th of that found in
cells from patients withmutated IDH2. Additionally, our in vitro enzyme
assay conditionsmay not exactly recapitulate those in themitochondrial
compartment, and thus the IDH2wt/R140Q reaction rate determined in
vitro may be an underestimation of the endogenous intracellular rate.
The IDH2wt/R140Q assay was useful for exploring preclinical thera-
peutic interventions as well. Oxaloacetate acted as a competitive inhib-
itor for the conversion of 2-KG to D-2-HG. The comparable afﬁnity of
IDH2wt/R140Q for oxaloacetate and 2-KG likely relates to their structural
similarity. The assay is also potentially useful to evaluate the capacity of
mutated IDH1 or IDH2 to produce D-2-HG in extracts of cancerous cells
and thereby take into account the amount of ‘active’ mutated IDH,
which may vary among patients. Additionally, the assay can possible
be employed to detect the effect of other, as yet undetected mutations,
which might also convert IDH to a D-2-HG-producing enzyme.
In conclusion, the IDH2wt/R140Q gain-of-function enzyme assay we
have developed is readily applicable to cultured lymphoblasts derived
from D-2-HGA type II patients. Chiral separation and quantiﬁcation of
stable-isotope-labeled D-2-hydroxyglutarate by UPLC-MS/MS provid-
ed a highly speciﬁc and sensitive method, and an assay which facili-
tates rapid identiﬁcation of D-2-HGA type II cells with IDH2wt/R140Q
gain-of-function. Perhaps most important, heterozygous IDH2wt/
R140Q mutations and gain-of-function activity are preserved intracel-
lularly following long-term storage and cell culture, highlighting the
utility of the lymphoblast model for future biochemical and therapeu-
tic explorations.
Supplementary materials related to this article can be found on-
line at doi:10.1016/j.bbadis.2011.08.006.Acknowledgements
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